Callisto Pharmaceuticals has restructured its license agreement with Genzyme Corp. for Atiprimod, Callisto’s lead drug candidate to treat advanced carcinoid cancer. In August 2002, Callisto’s subsidiary, Synergy, acquired worldwide exclusive rights to develop, manufacture and commercialize the drug from AnorMED, Inc.  Genzyme acquired AnorMED in November 2006. The revised agreement eliminates all milestone payments and reduces royalties owed to Genzyme. In return, Callisto will pay an upfront fe...